Screening hypercoagulable syndromes following stroke

Current Atherosclerosis Reports

Volumn 5, Issue 4, 2003, Pages 291-298

  Bushnell, Cheryl ^a   Goldstein, Larry B ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATED PROTEIN C; ANTITHROMBIN III; BLOOD CLOTTING FACTOR 5 LEIDEN; CARDIOLIPIN ANTIBODY; LUPUS ANTICOAGULANT; PHOSPHOLIPID ANTIBODY; PROTEIN S; PROTHROMBIN; THROMBOPLASTIN; VIPER VENOM;

ACTIVATED PROTEIN C RESISTANCE; ANTIPHOSPHOLIPID SYNDROME; ANTITHROMBIN III DEFICIENCY; BLOOD CLOTTING DISORDER; CEREBROVASCULAR ACCIDENT; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE MUTATION; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; HYPERCOAGULABILITY; INFLAMMATION; PARTIAL THROMBOPLASTIN TIME; PATIENT SELECTION; POLYMERASE CHAIN REACTION; PROTEIN C DEFICIENCY; PROTEIN S DEFICIENCY; REVIEW; SCREENING TEST; SERODIAGNOSIS; STROKE; THROMBOPHILIA; VEIN THROMBOSIS; VENOUS THROMBOEMBOLISM;

EID: 3142596443     PISSN: 15233804     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11883-003-0052-8     Document Type: Review

References (51)

1. American Heart Association: Heart Disease and Stroke Statistics - 2003 Update. http://www.americanheart.org. Accessed on February 3, 2003.
2. Sacco RL, Ellenberg JH, Mohr JP, et al.: Infarcts of undetermined cause: the NINCDS Stroke Data Bank. Ann Neurol 1989, 25:382-390.
3. Bushnell CD, Goldstein LB: Diagnostic testing for coagulopathies in patients with ischemic stroke. Stroke 2000, 31:3067-3078.
4. Hankey GJ, Eikelboom JW, van Bockxmeer FM, et al.: Inherited thrombophilia in ischemic stroke and its pathogenic subtypes. Stroke 2001, 32:1793-1799.
5. Juul K, Tybjaerg-Hansen A, Steffensen R, et al.: The Copenhagen City Heart Study and 2 meta-analyses. Blood 2002, 100:3-10.
6. Vandenbroucke JP, Koster T, Reitsma PH, et al.: Increased risk of venous thrombosis in oral-contraceptive users who are carriers of factor V Leiden mutation. Lancet 1994, 344:1453-1457.
7. Martinelli I, Landi G, Merati G, et al.: Factor V gene mutation is a risk factor for cerebral venous thrombosis. Thromb Haemost 1996, 75:393-394.
8. Zuber M, Toulon P, Marnet L, Mas JL: Factor V Leiden mutation in cerebral venous thrombosis. Stroke 1996, 27:1721-1723.
9. Salomon O, Steinberg D, Zivelin A, et al.: Single and combined prothrombotic factors in patients with idiopathic venous thromboembolism: prevalence and risk assessment. Arterioscler Thromb Biol 1999, 19:511-518.
10. Szolnoki Z, Somogyvari F, Kondacs A, et al.: Evaluation of the roles of the Leiden V mutation and ACE I/D polymorphism in subtypes of ischaemic stroke. J Neurol 2001, 248:756-761.
11. Seligsohn U, Lubetsky A: Medical progress: genetic susceptibility to venous thrombosis. N Engl J Med 2001, 344:1222-1231.
12. Longstreth WT Jr, Rosendaal FR, Siscovick DS, et al.: Risk of stroke in young women and two prothrombotic mutations: factor V Leiden and prothrombin gene variant (G20210A). Stroke 1998, 29:577-580.
13. Pezzini A, Del Zotto E, Magoni M, et al.: Inherited thrombophilic diosrders in young adults with ischemic stroke and patient foramen ovale. Stroke 2003, 34:28-33.
14. Kelly P, Rosand J, Kistler J, et al.: Homocysteine, MTHFR 677C-> T polymorphism, and risk of ischemic stroke. Results of a meta-analysis. Neurology 2002, 59:529-536.
15. Eikelboom JW, Lonn E, Genest J, et al.: Homocyst(e)ine and cardiovascular disease: a critical review of the epidemiologic evidence. Ann Intern Med 1999, 131:363-375.
16. Ray J: Meta-analysis of hyperhomocysteinemia as a risk factor for deep-vein thrombosis. Arch Intern Med 1998, 158:2101-2106.
17. Madonna P, de Stefano V, Coppola A, et al.: Hyperhomocysteinemia and other inherited prothrombotic conditions in young adults with a history of ischemic stroke. Stroke 2002, 33:51-56.
18. Margaglione M, DiMinno G, Grandone E, et al.: Plasma lipoprotein(a) levels in subjects attending a metabolic ward: discrimination between individuals with and without a history of ischemic stroke. Arterioscler Thromb Biol 1996, 16:120-128.
19. van Kooten F, van Krimpen J, Dippel DW, et al.: Lipoprotein(a) in patients with acute cerebral ischemia. Stroke 1996, 27:1231-1235.
20. Nagayama M, Shinohara Y, Nagayama T: Lipoprotein(a) and ischemic cerebrovascular disease in young adults. Stroke 1994, 25:74-78.
21. Ridker PM, Stampfer MJ, Hennekens CH: Plasma concentration of lipoprotein (a) and the risk of future stroke. JAMA 1995, 273:1269-1273.
22. Milionis HJ, Winder AF, Mikhailidis DP: Lipoprotein (a) and stroke. J Clin Pathol 2000, 53:487-496.
23. Dahlen GH: Lp(a) lipoprotein in cardiovascular disease. Atherosclerosis 1994, 108:111-126.
24. Etingin O, Hajjar D, Hajjar K, et al.: Lipoprotein (a) regulates plasminogen activator inhibitor-1 expression in endothelial cells: a potential mechanism in thrombogenesis. J Biol Chem 1991, 288:2459-2465.
25. Finazzi G, Brancaccio V, Moia M, et al.: Natural history and risk factors for thrombosis in 360 patients with antiphospholipid antibodies: a four-year prospective study from the Italian Registry. Am J Med 1996, 100:530-536.
26. Wilson WA, Gharavi AE, Koike T, et al.: International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop. Arthritis Rheum 1999, 42:1309-1311.
27. Brey RL, Escalante A: Neurological manifestations of antiphospholipid antibody syndrome. Lupus 1998, 7(suppl 2):S67-S74.
28. Rosove MH, Brewer PM: Antiphospholipid thrombosis: clinical course after the first thrombotic event in 70 patients. Ann Intern Med 1992, 117:303-308.
29. The Antiphospholipid Antibodies in Stroke Study (APASS) Group: Anticardiolipin antibodies are an independent risk factor for first ischemic stroke. Neurology 1993, 43:2069-2073.
30. Tuhrim S, Rand JH, Wu XX, et al.: Elevated anticardiolipin antibody titer is a stroke risk factor in a multiethnic population independent of isotype or degree of positivity. Stroke 1999, 30:1561-1565.
31. Tanne D, D'Olhaberriague L, Trivedi AM, et al.: Anticardiolipin antibodies and mortality in patients with ischemic stroke: A prospective follow-up study. Neuroepidemiology 2002, 21:93-99.
32. Heinzlef O, Abuaf N, Cohen A, Amarenco P: Recurrent stroke and vascular events in elderly patients with anticardiolipin antibodies: a prospective study. J Neurol 2001, 248:373-379.
33. Brey RL, Abbott RD, Curb JD, et al.: b2-Glycoprotein 1-dependent anticardiolipin antibodies and risk of ischemic stroke and myocardial infarction. The Honolulu Heart Program. Stroke 2001, 32:1701-1706.
34. Pierangeli SA, Stewart M, Silva LK, Harris EN: An antiphospholipid wet workshop: 7th international symposium on antiphospholipid antibodies. J Rheum 1998, 25:156-160.
35. Muir KW, Squire IB, Alwan W, Lees KR: Anticardiolipin antibodies in an unselected stroke population. Lancet 1994, 344:452-456.
36. Horbach DA, von Oort E, Donders RC, et al.: Lupus anticoagulant is the strongest risk factor for both venous and arterial thrombosis in patients with systemic lupus erythematosus. Comparison between different assays for the detection of antiphospholipid antibodies. Thromb Haemost 1996, 76:916-924.
37. Nojima J, Suehisa E, Akita N, et al.: Risk of arterial thrombosis in patients with anticardiolipin antibodies and lupus anticoagulant. Br J Haematol 1997, 96:447-450.
38. Levine SR, Brey RL, Sawaya KL, et al.: Recurrent stroke and thrombo-occlusive events in the antiphospholipid syndrome. Ann Neurol 1995, 38:119-124.
39. Khamashta MA, Cuadrado MJ, Mujic F, et al.: The management of thrombosis in the antiphospholipid-antibody syndrome. N Engl J Med 1995, 332:993-997.
40. Bushnell CD, Siddiqi Z, Morgenlander JC, Goldstein LB: Use of specialized coagulation testing in the evaluation of patients with acute ischemic stroke. Neurology 2001, 56:624-627.
41. Bushnell CD, Siddiqi Z, Goldstein LB: Improving patient selection for specialized coagulation testing in the setting of acute ischemic stroke. Neurology 2001, 57:1333-1335.
42. Comp PC: Laboratory evaluation of protein S status. Sem Thromb Hemost 1990, 16:177-181.
43. Mayer SA, Sacco RL, Hurlet-Jensen A, et al.: Free protein S deficiency in acute ischemic stroke. A case-control study. Stroke 1993, 24:224-227.
44. Triplett DA: Antiphospholipid antibodies and thrombosis. A consequence, coincidence, or cause? Arch Pathol Lab Med 1993, 117:78-88.
45. Tanne D, D'Olhaberriague L, Schultz LR, et al.: Anticardiolipin antibodies and their associations with cerebrovascular risk factors. Neurology 1999, 52:1368-1373.
46. Stampfer MJ, Malinow MR, Willett WC, et al.: A prospective study of plasma homocyst(e)ine and risk of myocardial infarction in US physicians. JAMA 1992, 268:877-881.
47. Craig W, Ledue T: Lipoprotein(a) and the acute phase response. Clin Chim Acta 1992, 210:231-232.
48. Sackett DL, Haynes RB, Guyatt GH, Tugwell P: Clinical Epidemiology. In A Basic Science for Clinical Medicine, edn 2. Boston: Little, Brown, and Company; 1991.
49. Bushnell CD, Goldstein LB: Homocysteine testing in patients with acute ischemic stroke. Neurology 2002, 59:1541-1546.
50. Jacques PF, Rosenberg IH, Rogers F, et al.: Serum total homocysteine concentrations in adolescent and adult Americans: result from the third National Health and Nutrition Examination Survey. Am J Clin Nutr 1999, 69:482-489.
51. Bushnell CD, Goldstein LB: Physician knowledge and practices in the evaluation of coagulopathies in stroke patients. Stroke 2002, 33:948-953.